Design efficiency in dose finding studies

DOI10.1016/S0167-9473(02)00323-7zbMath1429.62583OpenAlexW2002952151MaRDI QIDQ956828

Jean Maccario, John O'Quigley, Xavier Paoletti

Publication date: 26 November 2008

Published in: Computational Statistics and Data Analysis (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/s0167-9473(02)00323-7

zbMATH Keywords

efficiencyoptimalityclinical trialsdose findingphase I designs

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Related Items

Target toxicity design for phase I dose-finding ⋮ Continual reassessment and related dose-finding designs ⋮ A modified Huber loss function for continual reassessment methods in clinical trials ⋮ Adaptive clinical trial designs for phase I cancer studies

Cites Work

• Unnamed Item
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• Miscellanea. A stopping rule for the continual reassessment method
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• A Curve‐Free Method for Phase I Clinical Trials
• Non-parametric optimal design in dose finding studies